1. Scrip
  2. >>Business
  3. >>Strategy

A Star Is Born? HERCULES Data Shine At ASH For Ablynx's Caplacizumab

 
• By Lucie Ellis-Taitt

Strong Phase III HERCULES data mean Ablynx's caplacizumab is likely to sail through regulatory proceedings next year, becoming the first approved therapy for the rare blood disease, acquired thrombotic thrombocytopenic purpura.

SC1712_constellation Hercules_687159919_1200.jpg
Written in the stars: approvals expected in 2018 follwoing strong data for Ablynx's caplacizumab in HERCULES trial • Source: Shutterstock

Ablynx NV has presented more positive data for caplacizumab - which looks set to become the first drug approved for rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) - that highlight potential selling points likely to win over payers if the drug is successful with regulators.

Analysts have called caplacizumab a "game changer" for Ablynx since the company reported the positive data for the drug this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.